Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Organovo Holdings ( (ONVO) ) has provided an update.
On April 24, 2025, Organovo Holdings officially changed its name to VivoSim Labs, Inc., reflecting its strategic shift towards providing technologies that support the FDA’s move away from animal models. VivoSim has emerged from stealth mode to offer innovative NAM models that leverage AI and human organoid models, aiming to disrupt the $10 billion animal testing market by providing more predictive and ethically sound alternatives. This transition is expected to significantly impact the drug development process, potentially reducing clinical trial failures and development costs, while aligning with the FDA’s vision of accelerating drug evaluation and reducing animal use.
More about Organovo Holdings
VivoSim Labs, Inc., formerly known as Organovo Holdings, operates in the biotechnology industry, focusing on providing advanced non-animal testing models for drug discovery and development. The company specializes in liver and intestinal toxicology insights using new approach methodologies (NAM) models, aiming to replace traditional animal testing methods.
YTD Price Performance: -63.04%
Average Trading Volume: 738,833
Technical Sentiment Signal: Strong Buy
Current Market Cap: $3.42M
Find detailed analytics on ONVO stock on TipRanks’ Stock Analysis page.